Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | OXTR | P30559 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3814924 | 0.79 | OXTR (0.47) | CCR2OXTR | |
| SCHEMBL3815446 | 0.79 | OXTR (0.47) | CCR2OXTR | |
| SCHEMBL3813549 | 0.76 | OPRL1 (0.54) | CCR2OXTR | |
| SCHEMBL3812736 | 0.75 | SIGMAR1 (0.53) | — | |
| SCHEMBL3812490 | 0.74 | CCR2 (0.47) | CCR2OXTR | |
| SCHEMBL3810273 | 0.73 | OXTR (0.47) | OXTR | |
| SCHEMBL24433929 | 0.72 | CCR2 (0.46) | CCR2OXTRNR1H2NR1H3 | |
| SCHEMBL13314914 | 0.71 | TP53 (0.42) | — | |
| SCHEMBL4412826 | 0.71 | GRIN2B (0.49) | NR1H2NR1H3 | |
| SCHEMBL3813558 | 0.70 | CCR2 (0.48) | CCR2OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385514-B9 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO CELTIQUE SA (LU) | 2009-08-12 | — | — | EP | claimed |
| EP-1385514-B1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO CELTIQUE SA (LU) | 2008-11-05 | — | — | EP | claimed |
| US-20030018041-A1 | Spiroindene and spiroindane compounds | PURDUE PHARMA L.P. | 2003-01-23 | — | — | US | claimed |
| EP-1385514-B9 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO CELTIQUE SA (LU) | 2009-08-12 | — | — | EP | disclosed |
| EP-2033644-A1 | Spiroindene and spiroindane compounds | EURO-CELTIQUE S.A. (LU) | 2009-03-11 | — | — | EP | disclosed |
| EP-1385514-B1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO CELTIQUE SA (LU) | 2008-11-05 | — | — | EP | disclosed |
| US-6828440-B2 | Analgesics; side effect reduction | EURO-CELTIQUE, S.A. (LU) | 2004-12-07 | — | — | US | disclosed |
| US-20030018041-A1 | Spiroindene and spiroindane compounds | PURDUE PHARMA L.P. | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018041-A1 | Spiroindene and spiroindane compounds | NR3C2, REN, NR1I2 | CCR2 334/4885OXTR 959/4885NR1H2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.